126.88
前日終値:
$124.50
開ける:
$126.055
24時間の取引高:
7.36M
Relative Volume:
1.08
時価総額:
$220.05B
収益:
$41.95B
当期純損益:
$13.40B
株価収益率:
16.59
EPS:
7.65
ネットキャッシュフロー:
$6.35B
1週間 パフォーマンス:
+1.96%
1か月 パフォーマンス:
-4.36%
6か月 パフォーマンス:
+9.27%
1年 パフォーマンス:
+13.84%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABT
Abbott Laboratories
|
126.88 | 220.05B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
93.67 | 138.54B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
350.28 | 132.98B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
82.90 | 105.84B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
69.40 | 39.98B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-08 | 開始されました | Oppenheimer | Outperform |
2024-09-19 | 開始されました | Piper Sandler | Overweight |
2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-04-20 | 繰り返されました | Barclays | Overweight |
2023-04-20 | 繰り返されました | Bernstein | Outperform |
2023-04-20 | 繰り返されました | JP Morgan | Overweight |
2023-04-20 | 繰り返されました | Raymond James | Outperform |
2023-04-20 | 繰り返されました | UBS | Buy |
2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
2023-03-29 | 開始されました | UBS | Buy |
2022-10-26 | 開始されました | Mizuho | Neutral |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-07-06 | 開始されました | Wolfe Research | Underperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | UBS | Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
2021-10-14 | 開始されました | Redburn | Neutral |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
2020-09-11 | 開始されました | Wolfe Research | Outperform |
2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
2018-11-30 | アップグレード | Goldman | Neutral → Buy |
2018-10-16 | 開始されました | Barclays | Overweight |
2018-06-27 | 開始されました | Bernstein | Outperform |
2018-01-30 | 繰り返されました | Citigroup | Neutral |
2018-01-25 | 繰り返されました | Stifel | Buy |
2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
2018-01-03 | 開始されました | Evercore ISI | Outperform |
2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
With 79% ownership of the shares, Abbott Laboratories (NYSE:ABT) is heavily dominated by institutional owners - simplywall.st
Immunoassay Analyzers Market Size to Hit USD 10.16 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories - Nasdaq
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $32K Worth of Abbott Laboratories Stock - Benzinga
Seeking Clues to Abbott (ABT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Nasdaq
TD Cowen maintains Abbott Labs stock Buy rating, $135 target - Investing.com India
TD Cowen maintains Abbott Labs stock Buy rating, $135 target By Investing.com - Investing.com UK
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus - Zacks Investment Research
Immunoassay Market to Witness Remarkable Growth with Abbott - openPR.com
Positive Outlook for Abbott Laboratories: Strong Growth and New Product Launches Support Buy Rating - TipRanks
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - TradingView
Abbott (ABT) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) institutional investors lost 5.9% over the past week but have profited from longer-term gains - Yahoo Finance
Abbott bolsters its Heart Failure leadership - MassDevice
Cytokine Market Is Booming So Rapidly 2025-2032 -Abbott, AB - openPR.com
Oppenheimer maintains Abbott stock Outperform with $134 target By Investing.com - Investing.com India
Oppenheimer maintains Abbott stock Outperform with $134 target - Investing.com
The Zacks Analyst Blog Highlights Molson Coors, CenterPoint Energy, WEC Energy, Abbott Laboratories and HCA Healthcare - Yahoo Finance
Is Abbott Laboratories (ABT) the Most Profitable Dividend Stock to Buy Now? - Insider Monkey
Citigroup Adjusts Abbott Laboratories Price Target to $155 From $160, Maintains Buy Rating - MarketScreener
Abbott Laboratories (ABT): One of the Best Dividend Kings to Buy for Safe Dividend Growth - Insider Monkey
Abbott Laboratories (ABT) Maintains Strong ROE Amid Stock Decline - GuruFocus
Will Weakness in Abbott Laboratories' (NYSE:ABT) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Here’s What to Expect From Abbott Laboratories’ Next Earnings Report - Nasdaq
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? - Yahoo
Piper Sandler maintains Overweight on Abbott Labs with $133 target - Investing.com
Reasons to Add ABT Stock to Your Portfolio Right Now - TradingView
Q4 Rundown: Abbott Laboratories (NYSE:ABT) Vs Other Medical Devices & SuppliesDiversified Stocks - Yahoo Finance
Unsanitary Practices Persist at Baby Formula Factory Whose Shutdown Led to Mass Shortages, Workers Say - ProPublica
Leadless Pacemakers Market Deep Research 2025-2032 | Abbott - openPR.com
Impact of Trump tariffs on med tech proving difficult to anticipate - BioWorld MedTech
Global Expansion in EPD and Innovations Support Abbott Stock - Nasdaq
Similac infant formula class action alleges products contain heavy metals - Class Action Lawsuits
FISH Probe Market Is Booming So Rapidly 2025-2032Abbott Laboratories, Agilent Technologies Inc - openPR.com
Hematology Diagnostics Market is Booming Worldwide | Abbott, Boule Diagnostics, and Danaher are the Major Stakeholders – Arizton - Barchart.com
Abbott Laboratories consolidates media with Spark Foundry - Ad Age
Abbott launches next-gen delivery system for Proclaim DRG neurostim - MassDevice
Abbott joins AFib-treating race with tech that may skip general anesthesia - Star Tribune
Abbott Laboratories (NYSE:ABT) Shows Promising Results in Heart Valve Device Study - simplywall.st
Hematology Market Is Booming Worldwide | Abbott Laboratories, Sysmex Co., Beckman Coulter, Horiba - openPR.com
ABT Stock Gains Following the Positive TRILUMINATE Trial Results - TradingView
ABC's 'Abbott Elementary' teams up with MilliporeSigma to bring mobile science lab to San Jose elementary school students - ABC7 San Francisco
Abbott (ABT) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Sector Update: Health Care Stocks Mixed in Afternoon Trading - MarketScreener
Abbott Laboratories’ TriClip Device: A Promising Investment Backed by Positive TRILUMINATE Trial Results - TipRanks
Abbott TriClip offers substantial improvements in study - MassDevice
Abbott Laboratories Says Trial Results Show Benefits of TriClip System for People With Leaky Heart Valves - MarketScreener
The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology - Yahoo Finance
Abbott's Revolutionary Heart Valve Treatment Cuts Hospitalizations by 27% in Landmark Trial - Stock Titan
Abbott Laboratories’ SWOT analysis: stock outlook amid PFA system approval - Investing.com
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):